Ambient ultrafine particles alter lipid metabolism and HDL anti-oxidant capacity in LDLR-null mice

J Lipid Res. 2013 Jun;54(6):1608-1615. doi: 10.1194/jlr.M035014. Epub 2013 Apr 6.

Abstract

Exposure to ambient particulate matter (PM) is a risk factor for cardiovascular diseases. The redox-active ultrafine particles (UFPs) promote vascular oxidative stress and inflammatory responses. We hypothesized that UFPs modulated lipid metabolism and anti-oxidant capacity of high density lipoprotein (HDL) with an implication in atherosclerotic lesion size. Fat-fed low density lipoprotein receptor-null (LDLR⁻/⁻ mice were exposed to filtered air (FA) or UFPs for 10 weeks with or without administering an apolipoprotein A-I mimetic peptide made of D-amino acids, D-4F. LDLR⁻/⁻ mice exposed to UFPs developed a reduced plasma HDL level (P < 0.01), paraoxonase activity (P < 0.01), and HDL anti-oxidant capacity (P < 0.05); but increased LDL oxidation, free oxidized fatty acids, triglycerides, serum amyloid A (P < 0.05), and tumor necrosis factor α (P < 0.05), accompanied by a 62% increase in the atherosclerotic lesion ratio of the en face aortic staining and a 220% increase in the cross-sectional lesion area of the aortic sinus (P < 0.001). D-4F administration significantly attenuated these changes. UFP exposure promoted pro-atherogenic lipid metabolism and reduced HDL anti-oxidant capacity in fat-fed LDLR⁻/⁻ mice, associated with a greater atherosclerotic lesion size compared with FA-exposed animals. D-4F attenuated UFP-mediated pro-atherogenic effects, suggesting the role of lipid oxidation underlying UFP-mediated atherosclerosis.

Keywords: D-4F; atherosclerosis; high density lipoprotein; low density lipoprotein receptor-null.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Antioxidants / metabolism*
  • Apolipoprotein A-I / pharmacology
  • Atherosclerosis / chemically induced
  • Atherosclerosis / genetics
  • Atherosclerosis / metabolism
  • Dietary Fats / pharmacology*
  • Lipid Metabolism / drug effects*
  • Lipid Metabolism / genetics
  • Lipoproteins, HDL / metabolism*
  • Mice
  • Mice, Knockout
  • Oxidation-Reduction / drug effects
  • Particulate Matter / adverse effects*
  • Particulate Matter / pharmacology
  • Peptidomimetics / pharmacology
  • Receptors, LDL*

Substances

  • Antioxidants
  • Apolipoprotein A-I
  • D-4F peptide
  • Dietary Fats
  • Lipoproteins, HDL
  • Particulate Matter
  • Peptidomimetics
  • Receptors, LDL